Back to top
more

ADC Therapeutics (ADCT)

(Delayed Data from NYSE)

$2.66 USD

2.66
383,942

-0.15 (-5.34%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $2.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ADCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

ADC Therapeutics SA [ADCT]

Reports for Purchase

Showing records 21 - 40 ( 57 total )

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 21

12/16/2021

Company Report

Pages: 4

Key ASH Takeaways; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 22

11/04/2021

Company Report

Pages: 4

ZYNLONTA 3Q21 Sales Best Consensus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 23

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ADCT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 24

08/10/2021

Company Report

Pages: 4

Polivy Phase 3 POLARIX Data Bode Well for ZYNLONTA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 25

08/04/2021

Company Report

Pages: 4

2Q21 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 26

05/14/2021

Company Report

Pages: 5

ZYNLONTA in Launch Mode; 1Q21 Financial Results; Modulating PT to $55

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 27

04/26/2021

Company Report

Pages: 5

Zynlonta (Lonca) Wins FDA Approval Ahead of Schedule; Raising PT to $57

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 28

03/19/2021

Company Report

Pages: 4

2020 Financials Reported; Raising PT to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 29

02/05/2021

Company Report

Pages: 4

Camidanlumab Tesirine Pivotal Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 30

01/08/2021

Company Report

Pages: 4

Loncastuximab Tesirine Expanded Access Program Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 31

12/14/2020

Company Report

Pages: 4

New China-Focused Firm Formed With Overland Pharma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 32

12/09/2020

Company Report

Pages: 5

ASH Presentations Reinforce Pipeline, In Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 33

11/20/2020

Company Report

Pages: 4

FDA Sets Approval Decision Date for Lonca in R/R DLBCL; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 34

11/17/2020

Company Report

Pages: 4

3Q20 Financials Reported; Key ASH Presentations Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 35

11/03/2020

Company Report

Pages: 4

ADC Doses First Patient With Cami + Keytruda; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 36

10/30/2020

Company Report

Pages: 4

ADC Defines Terms of Genmab Collaboration; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Medical - Biomedical and Genetics

Record: 37

10/29/2020

Company Report

Pages: 61

Acing the Field of Antibody-Drug Conjugates; Initiating at Buy and $47 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 150.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Communication - Infrastructure

Record: 38

02/02/2011

Company Report

Pages: 3

We are discontinuing coverage due to analyst departure

Provider: AURIGA USA

Analyst: BERENBAUM D

Price: 10.00

Research Provided by a Third Party

Company: ADC Therapeutics SA

Industry: Communication - Infrastructure

Record: 39

11/30/2010

Company Report

Pages: 7

Price: 24.95

Company: ADC Therapeutics SA

Industry: Communication - Infrastructure

Record: 40

11/24/2010

Industry Report

Pages: 4

Tailwind from Broadband Stimulus Bill Nears

Provider: AURIGA USA

Analyst: SARKAR C

Price: 10.00

Research Provided by a Third Party
// eof